Introduction
============

Trigger digit, also known as stenosing tenosynovitis, is characterized by an inability to flex or extend the digit smoothly, often with pain over the palmar aspect of the metacarpophalangeal joint.[@b1-oajsm-7-143]--[@b3-oajsm-7-143] This condition develops when thickening of the tendon sheath at the first annular ligament's pulley and subsequent constriction of the tendon prevents it from gliding through. Pinching of the tendon often causes nodule formation,[@b1-oajsm-7-143],[@b3-oajsm-7-143],[@b4-oajsm-7-143] and patients typically present with a locking, popping sensation as the nodule catches at the constriction.[@b1-oajsm-7-143],[@b2-oajsm-7-143],[@b4-oajsm-7-143] In some cases, it resolves spontaneously; however, if left untreated, trigger digit may gradually progress until the affected finger or thumb is permanently locked in flexion.[@b1-oajsm-7-143] Histologically, the A1 pulley exhibits fibrocartilaginous metaplasia, and in the tendon tissue, areas of hyalinosis, mucoid degeneration, and chondral metaplasia are found.[@b5-oajsm-7-143] It is the most common flexor tendinopathy,[@b2-oajsm-7-143] with highest incidence in women (75%) and in those aged between 52 and 62 years,[@b6-oajsm-7-143] with the fourth digit (ring finger) and thumb most often affected.[@b3-oajsm-7-143]

Trigger digits are usually idiopathic; however, some authors argue that there is a possible correlation with excessive use of the hand.[@b7-oajsm-7-143],[@b8-oajsm-7-143] Other potential risk factors include rheumatoid arthritis, diabetes mellitus, carpal tunnel syndrome, Dupuytren's disease, amyloidosis, hypothyroidism, mucopolysaccharide storage disorders, congestive heart failure, and genetic predisposition.[@b4-oajsm-7-143],[@b9-oajsm-7-143],[@b10-oajsm-7-143]

Treatment aims to eliminate pain and stop triggering. Currently accepted conservative treatments include pain medication, orthoses, physiotherapy, and corticosteroid injections.[@b3-oajsm-7-143] Corticosteroid injection has the greatest success rate;[@b11-oajsm-7-143] however, it is still reported to be effective only in 57% of the patients.[@b6-oajsm-7-143] Moreover, multiple injections may cause tendon rupture, a course of more than two injections is reported to almost never be successful, and repeated injections before surgery are not cost-effective. Thus, for many patients, corticosteroid injection is not a long-term treatment option.[@b2-oajsm-7-143],[@b12-oajsm-7-143],[@b13-oajsm-7-143]

Surgical treatment involves percutaneous and open release of the A1 pulley.[@b2-oajsm-7-143],[@b3-oajsm-7-143] Both are reported to be similarly effective and superior to corticosteroid injection,[@b14-oajsm-7-143] with remission of symptoms achieved in 97%--100% of cases.[@b14-oajsm-7-143]--[@b17-oajsm-7-143] However, it is associated with longer recovery times and more complications including tendon bowstringing, digital ulnar drift, and nerve injuries.[@b3-oajsm-7-143] Due to these possible complications and as guidelines by the American College of Occupational and Environmental Medicine[@b18-oajsm-7-143] recommend surgery only when conservative treatments have failed, radial extracorporeal shock wave therapy (rESWT) could play a role as a noninvasive alternative.

rESWT is a noninvasive and safe therapy and has been used in the management of tendon pathologies since the early 1990s in order to alleviate pain and improve function. A radial shockwave is a low-energy wave that is generated when a projectile in the hand piece of the rESWT device is accelerated by a compressed air source and hits a metal applicator. The pressure wave is transmitted to the patient's skin through ultrasound gel and spreads as a spherical (radial) wave into the tissue. The energy is highest at the tip of the applicator and decreases peripherally by the square of the distance.[@b19-oajsm-7-143]--[@b21-oajsm-7-143] The biological mechanisms by which rESWT induces therapeutic effects on pathological tendon tissue are not completely elucidated, although it is suggested that shockwaves may facilitate the healing process through the disruption of avascular, damaged tissues, stimulation of growth factor release, stem cell recruitment, and neovascularisation.[@b22-oajsm-7-143]--[@b25-oajsm-7-143]

rESWT has been used to treat numerous other tendinopathies, such as epicondylitis,[@b22-oajsm-7-143],[@b26-oajsm-7-143] plantar fasciitis,[@b26-oajsm-7-143]--[@b28-oajsm-7-143] patellar tendinopathy,[@b21-oajsm-7-143],[@b26-oajsm-7-143],[@b29-oajsm-7-143] shoulder calcific tendinitis,[@b19-oajsm-7-143],[@b30-oajsm-7-143],[@b31-oajsm-7-143] proximal hamstring tendinopathy,[@b32-oajsm-7-143] and medial tibial stress syndrome.[@b20-oajsm-7-143],[@b33-oajsm-7-143] However, to the authors' knowledge, to date, no studies on rESWT and trigger digit have been conducted.

Acknowledging the poor efficacy and the prolonged rehabilitation of traditional conservative treatments, possible complications associated with surgery, and the evidence that rESWT (with the additional advantage that it is noninvasive) is effective in the treatment of other tendinopathies, the aim of this study was to determine whether rESWT is a safe and effective treatment for trigger digit. Therefore, the functional improvement and mean pain reduction over a 1-year follow-up period were assessed. In addition, the individualised treatment protocol was retrospectively analysed to look for correlations between pre-treatment symptom duration, the number of rESWT sessions required until recovery, and the 1-year post-treatment visual analog scale score.

Materials and methods
=====================

Study subjects
--------------

Ethical approval for this retrospective, uncontrolled cohort study was granted by the Thessaloniki Clinic Institutional Review Board (ART No 2012-03). All participants provided written informed consent. The study included 44 adults (49 fingers/thumbs; 39 adults with single-digit pathology and five with two-digit pathology) who were sequentially diagnosed with trigger digit by a consultant in Sport and Exercise Medicine outpatient clinic between 2009 and 2013 ([Table 1](#t1-oajsm-7-143){ref-type="table"}). The diagnosis was based on clinical history and examination. Patients underwent ultrasound imaging to assess thickening of the A1 pulley.

The mean age of the study participants was 49±10 years (ranging from 32 to 71 years). Of the total participants, 33 participants (67.3%) were women and 16 (32.7%) were men. The average pretreatment symptom duration was 5±5.7 months (ranging from 1 to 24 months); 19 fingers/thumbs (38.8%) had symptoms for \<3 months, 19 fingers/thumbs (38.8%) from 3 to 6 months, 4 fingers/thumbs (8.2%) from 6 to 12 months, and 7 (14.3%) fingers/thumbs from 12 to 24 months.

Inclusion criteria
------------------

Patients with Grade 2 and Grade 3 trigger digit according to Quinnell's classification (Grade 0: normal finger movements, Grade 1: uneven finger movements, Grade 2: actively correctable triggering, Grade 3: passively correctable triggering, and Grade 4: locked digit) were included.[@b34-oajsm-7-143]

Exclusion criteria
------------------

Patients with Quinnell's Grade 1 and Grade 4 trigger digit were excluded from the study, and Grade 4 was referred for surgery. The exclusion criteria were as follows: traumatic trigger digit, age \<18 years, rheumatoid arthritis, generalized polyarthritis, local infection, and history of malignancy, cervical pain, or previous surgery for trigger digit. Possible differential diagnoses such as infective tenosynovitis, metacarpophalangeal articular pathology, gamekeeper's thumb, and Dupuytren's contracture were excluded by clinical examination and ultrasound imaging.

Procedure and equipment
-----------------------

Treatment was administered by using the Storz Medical Masterplus^®^ MP200 (Storz Medical, Tägerwilen, Switzerland) rESWT device. At each session, 2,000 impulses were applied to the painful area overlying the pathological flexor tendon at a frequency of 5--6 Hz. The device pressure varied from 1 to 3 bars depending on the patient's individual pain tolerance; it was kept low enough to ensure that pain was tolerable, but high enough to have a therapeutic effect. Treatment sessions took place weekly until symptoms subsided, and thus, the total number of treatment sessions for each patient were based on the individual response to treatment.

Ultrasound gel was used for the transmission of shock-waves to the patient's skin. No local anesthesia was administered as it is known to reduce the efficacy of ESWT.[@b27-oajsm-7-143],[@b28-oajsm-7-143],[@b35-oajsm-7-143],[@b36-oajsm-7-143] The painful area was covered in a longitudinal pattern starting at the point of maximum pain determined by patient's feedback. At the end of each session, the patients were advised to use the finger normally, and they underwent no other treatments during the follow-up period of the study. All the patients were free to seek additional care (surgical consultation) if unsatisfied with improvement.

Outcome measures and follow-up
------------------------------

Patients were assessed at baseline (pretreatment) and at 1-, 3-, and 12-months follow-up appointments (posttreatment) when a full clinical examination was performed ([Figure 1](#f1-oajsm-7-143){ref-type="fig"}). All patients were present during the follow-up period. The Roles and Maudsley score was used to assess functional outcome after rESWT treatment. This is a 4-point scale where 1 indicates an "excellent" result, 2 a "good" result, 3 a "fair" result, and 4 a "poor" posttreatment result. "Excellent" and "good" results were considered a success, meaning that the patients had full movement of the affected finger and activity was not restricted. "Fair" and "poor" results were considered a failure, bearing identical or even worse symptoms after rESWT treatment. These cases experienced some discomfort after prolonged activity or pain-limited activities.[@b37-oajsm-7-143]

Pain severity was measured using the standard VAS. A score of 10 indicated maximum pain and 0 the minimum. Primary outcome measures were functional improvement and mean VAS reductions at 1-, 3-, and 12-months posttreatment compared with baseline. A VAS reduction of 60% was considered a clinically positive result. Recurrence of symptoms was defined as a 1-year follow-up VAS score of ≥2.

The individualized protocols were also retrospectively analyzed in terms of the number of sessions required and the pressure used (bars). To do this, additional outcome measures were used to assess correlations, first, between pretreatment symptom duration and the number of rESWT sessions required until recovery and, second, between pretreatment symptom duration and the 1-year posttreatment VAS score.

Statistics
----------

Descriptive analysis was conducted, aiming at a comprehensive presentation of the patients' demographics (such as age and sex) and the distribution of the affected hands and fingers. Total number of rESWT sessions required, shockwave impulses, and pressure and frequency used were retrospectively analyzed as means. Mean VAS scores were calculated at each follow-up interval, and mean VAS reductions were assessed from the percentage decrease in mean pain level from the pretreatment (baseline) VAS. Significant differences between baseline VAS and follow-up VAS scores were assessed by using Wilcoxon signed rank test, and Monte Carlo simulation was used to test statistical significance. Quartile statistics were also used to describe VAS variables as a nonparametric test was used.

In order to assess the relationship between pretreatment pain duration (in months), the number of rESWT sessions required, and the 1-year follow-up VAS score posttreatment, Spearman's rank correlation coefficient was used.

A combination of Statistical Package for the Social Sciences Version 20 (IBM Corporation, Armonk, NY, USA) and Microsoft Excel (Microsoft Corporation, Redmond, WA, USA) was used to conduct all statistical analyses, and the confidence level was predefined at 95% (*α* =0.05) for all statistical analyses.[@b38-oajsm-7-143],[@b39-oajsm-7-143]

Results
=======

The average number of rESWT sessions required was 6±1.3 (ranging from 3 to 8). All the 44 subjects (49 digits) were treated with 2,000 impulses of shockwave per session at a mean pressure of 1.4±0.3 bar (ranging from 1 to 3) and a mean frequency of 5±0.4 Hz (ranging from 5 to 6; [Figure 2](#f2-oajsm-7-143){ref-type="fig"}).

From the total of 49 digits, one (2%) received three sessions, nine (18.4%) received four sessions, 12 (24.5%) received five sessions, 20 (40.8%) received six sessions, and 7 (14.3%) received eight sessions.

According to the Roles and Maudsley score, 73.5% (36) of the patients stated their functional post-rESWT treatment condition as "excellent" and 20.4% (10) as "good" ([Table 2](#t2-oajsm-7-143){ref-type="table"}). A "fair" functional post-rESWT treatment condition was stated in three cases (6.1%).

A statistically significant reduction in VAS scores was found between baseline and 1-month follow-up (*z*=−6.212, *P*\<0.001), between baseline and 3-month follow-up (*z*=−6.220, *P*\<0.001), and between baseline and 1-year follow-up (*z*=−6.209, *P*\<0.001). All the 49 cases had negative ranks with a mean rank of 25.00 in all cases. Pain score rating was 8.0 at baseline, 3.0 at 1-month posttreatment, and 1.0 both at 3-month and 1-year follow-up ([Figure 3](#f3-oajsm-7-143){ref-type="fig"} and [Table 3](#t3-oajsm-7-143){ref-type="table"}).

Three patients had recurrent symptoms at 1-year follow-up with the recurrence rate estimated at 6.1%; 34.7% (17 digits) had a VAS score of 0 (asymptomatic), 59.2% (29 digits) had a VAS score of 1.0, and 4.1% (two digits) had a VAS score of 2.0. In addition, no complications were reported in the subjects.

A strong positive Spearman's ρ correlation was found between pre-rESWT treatment symptoms duration and the number of sessions required (*r*=0.776, *P*\<0.001; [Figure 4](#f4-oajsm-7-143){ref-type="fig"}). Significant, positive, but weak correlation was also found to 1-year VAS with pretreatment symptoms duration (*r*=0.335, *P*=0.019).

Discussion
==========

Trigger digit caused by fibrocartilaginous metaplasia of the tendon sheath can be a chronic and progressive condition.[@b1-oajsm-7-143]--[@b3-oajsm-7-143] In the literature spontaneous recovery has been reported in 20%--29% of cases; however, in some untreated patients, the initial symptoms of intermittent pain, snapping or triggering progress over time, and long-standing cases may present with the affected finger or thumb locked in flexion.[@b1-oajsm-7-143]

According to the authors' knowledge, this is the first study conducted to assess the effectiveness of rESWT for trigger digit. Evidence from previous studies has found that rESWT is effective in the treatment of multiple other tendinopathies.[@b19-oajsm-7-143]--[@b33-oajsm-7-143],[@b40-oajsm-7-143],[@b41-oajsm-7-143] However, the specific biological mechanisms by which it induces therapeutic effects on pathological tendon tissue are not completely elucidated. Evidence from a recent study of human tendons suggested that the mechanical stimulus of ESWT aids tendon remodeling by promoting inflammatory and catabolic processes that are associated with the removal of damaged matrix constituents.[@b42-oajsm-7-143] In vitro studies have further suggested that ESWT increases tendon healing through the stimulation of cell proliferation and motility, neovascularization, and expression of critical differentiation genes.[@b43-oajsm-7-143] However, these in vitro findings cannot be automatically generalized to the in vivo conditions in human tendinopathies.

In the present study, statistically significant pain reductions (*P*\<0.001) and functional improvements were found through all midpoints during the 1-year follow-up in 93.1% of cases, whereas only three patients had recurrent symptoms at 1-year posttreatment assessment. According to this initial evidence, rESWT was proven to be a suitable treatment for trigger digit. The analysis of the individualized treatment protocols demonstrated that longer pretreatment symptom duration was positively correlated with more sessions required until recovery (*P*\<0.001) and a higher VAS score at 1-year posttreatment (*P*\<0.05).

rESWT compared with traditional treatments for trigger digit
------------------------------------------------------------

Of the currently accepted conservative treatments, including pain medications, orthoses, physiotherapy, and corticosteroid injection, corticosteroid injection is the most effective treatment. However, corticosteroid injection is effective in only 57% of the patients.[@b6-oajsm-7-143] Moreover, symptom recurrence at 1 year after injection is reported to be 33%--56%,[@b14-oajsm-7-143],[@b44-oajsm-7-143],[@b45-oajsm-7-143] and thus, surgery is often still required. The success rate is further decreased in certain patient groups, such as diabetics.[@b3-oajsm-7-143],[@b44-oajsm-7-143],[@b46-oajsm-7-143] The present study, with a recurrence rate of only 6.1% at 1-year posttreatment, would indicate a better outcome with rESWT than corticosteroid injection and all other conservative methods.

Surgery is widely accepted as the definitive treatment for trigger digit, with remission of symptoms reported to be achieved in 97%--100% of cases.[@b14-oajsm-7-143]--[@b17-oajsm-7-143] Consequently, in the present study, rESWT was offered only to the patients with Quinnell's[@b34-oajsm-7-143] Grade 2 or 3 trigger digit, and patients with Grade 4 were referred for surgery. Therefore, only the effectiveness of rESWT in the treatment of Grade 2 and 3 conditions was commented in the present study. For these cases of trigger digit, which are not yet a fixed deformity, the recurrence rate of only 6.1% at 1-year post-rESWT was reported. This suggests that rESWT is a promising, noninvasive alternative for the treatment of trigger digits before they become a fixed deformity (locked digit). rESWT is a conservative treatment modality without the longer recovery time and risk of complications such as nerve damage, infections, and painful scarring that are associated with surgery.[@b16-oajsm-7-143],[@b17-oajsm-7-143] Often quoted, minor complications of rESWT include bruising and redness. However, in the present study, no complications were reported, perhaps because a high pressure and high total energy flux density were not used.

Notably, in the present study, pain reductions continuously increased over the entire 1-year follow-up period. At 1-month posttreatment, the mean VAS score had reduced by 67% from baseline and at 12 months, it had reduced by 91%, providing excellent long-term efficacy of rESWT. Previous studies investigating shockwave therapy for various other tendinopathies have likewise demonstrated an increasing improvement in symptoms over the entire 1-year follow-up.[@b22-oajsm-7-143],[@b27-oajsm-7-143]

Treatment protocol
------------------

Although multiple, high-quality studies have demonstrated that rESWT is safe and effective in the treatment of various tendinopathies,[@b19-oajsm-7-143],[@b20-oajsm-7-143],[@b22-oajsm-7-143],[@b27-oajsm-7-143]--[@b31-oajsm-7-143] controversy exists over the optimum treatment protocol that should be used in terms of shockwave generation (focused or radial), energy density, the number and frequency of treatments, method of localization (using anatomical landmarks, clinical focusing, or image-guided focusing), and the use of concomitant anaesthesia.[@b27-oajsm-7-143],[@b29-oajsm-7-143]

In the present study, radial shockwaves were used because they allow the treatment of a larger tissue volume.[@b21-oajsm-7-143],[@b26-oajsm-7-143],[@b27-oajsm-7-143],[@b30-oajsm-7-143],[@b47-oajsm-7-143] The pathologically changed painful area of tendon is relatively large in trigger digit compared to insertional tendinopathies. Thus, radial waves are advantageous as the pathologic tissue is included in the wave propagation area. Moreover, ultrasound or fluoroscopy guidance is not required with rESWT, making the application easier.[@b19-oajsm-7-143],[@b26-oajsm-7-143],[@b48-oajsm-7-143] rESWT is also less painful than focused ESWT. This makes local anesthetic unnecessary and potentially improves treatment outcome as concomitant local anesthesia has been demonstrated to reduce ESWT efficacy.[@b27-oajsm-7-143],[@b28-oajsm-7-143],[@b35-oajsm-7-143],[@b36-oajsm-7-143]

With regard to pressure and the number of sessions prescribed, the protocol used in the present study was individualized to each patient. It has been demonstrated that when rESWT is used for the treatment of tendinopathy, there must be a balance between pressure and the number of sessions required. The higher the pressure, the greater the treatment effects; thus, less sessions are required, but pain during the treatment increases. The lower the pressure, the more sessions are required to have a therapeutic effect.[@b49-oajsm-7-143] Therefore, in the present study, pressure was set between 1.0 and 1.7 bars depending on each patient's individual pain tolerance. The pressure was kept low enough to ensure that the pain was tolerable, but high enough to have a therapeutic effect.

The total number of sessions prescribed was determined when symptoms resolved and ranged from 3 to 8, depending on the patient's individual response to treatment. Currently, there are no standardized guidelines for the number of rESWT sessions required when treating soft tissue conditions,[@b50-oajsm-7-143] although studies have suggested that multiple applications provide superior long-term results compared with a single application.[@b51-oajsm-7-143] Compared to other tendinopathies treated with rESWT, the finger is a rather painful area to treat. This might explain why comparatively low pressures have to be used.

Strengths of the study
----------------------

This is the first retrospective cohort study to evaluate the effectiveness of rESWT for the treatment of stenosing tenosynovitis of the digital flexor tendon (trigger digit). All patients completed the 1-year follow-up. Individualization of the protocol might be a further strength and provides a possible explanation for the high efficacy of rESWT demonstrated in the present study compared to that reported by most previous studies on rESWT for tendinopathy. To the authors' knowledge, all previous studies have applied a standardized number of treatments to the patients.

Limitations of the study
------------------------

Patients with a prior symptom duration ranging from 1 to 24 months were included, whereas most previous studies on rESWT have only investigated its effectiveness for more chronic tendinopathies (such as those with a prior symptomatic period of at least 6 months).[@b20-oajsm-7-143],[@b21-oajsm-7-143],[@b27-oajsm-7-143] As this study is a retrospective cohort study, it also has some inherent limitations that require consideration. There was no randomization, and there was no control group in this investigation. Furthermore, the number of subjects was relatively small in order to provide external validity to the present study. A comparative study with a control series will be more demonstrative.

Recommendations for the treatment of trigger digit with rESWT
-------------------------------------------------------------

The results demonstrate that there is no standard pressure or number of sessions that is suitable for everyone: some patients tolerate a higher pressure, and some require more treatments until recovery. With the individualized protocol, significant pain reductions were found and all patients found improvement. It was also found that pretreatment symptom duration is one of other possible factors that influence the number of sessions required by a patient. Shorter-term cases required fewer sessions and also had a lower VAS score at 1-year follow-up. Thus, the patients presenting with a longer history of symptoms need more rESWT sessions. According to the present study, varying the protocol according to each patient's tolerance and response to treatment is the best way to treat tendinopathies with rESWT.

Conclusion
==========

The present study provides initial evidence for the effectiveness of rESWT for the treatment of trigger digit. Randomized controlled trials are required to prove well the evidence of the rESWT effect.
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![Radial extracorporeal shockwave therapy mean VAS reduction and average pain level at follow-up time intervals.\
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###### 

Characteristics of patients and trigger digits receiving radial extracorporeal shockwave therapy

  Characteristics                               
  --------------------------------------------- ---------------------
  Sex                                           Patients (44)
   Male (%)                                     15 (34.1%)
   Female (%)                                   29 (65.9%)
  Hand affected:                                Patients (44)
   Right (%)                                    26 (59.1%)
   Left (%)                                     13 (29.5%)
  Bilateral (%)                                 5 (11.4%)
  Digit affected                                Fingers/thumbs (49)
   Thumb                                        22 (44.9%)
   Index                                        5 (10.2%)
   Third finger                                 7 (14.3%)
   Fourth finger                                13 (26.5%)
   Fifth finger                                 2 (4.1%)
  Quinnell's grade                              Fingers/thumbs (49)
   Grade 2 (actively correctable triggering)    24 (48%)
   Grade 3 (passively correctable triggering)   25 (52%)
  Age (years), mean (±SD)                       49.06 (±9.99)
  Duration of pain (months), mean (±SD)         5.09 (±5.72)

**Note:** Values are counts, number of patients (percentages) unless stated otherwise.

###### 

Roles and Maudsley score functional radial extracorporeal shockwave therapy treatment results

  Grade       Number of cases   Percent
  ----------- ----------------- ---------
  Excellent   36                73.5
  Good        10                20.4
  Fair        3                 6.1
  Poor        0                 0
  Total       49                100.0

###### 

Visual analog scale (VAS) scores means, standard deviation, and variance at baseline and follow-up

                  n    Mean   Standard deviation   Minimum   Maximum   Percentiles         
  --------------- ---- ------ -------------------- --------- --------- ------------- ----- -----
  Baseline_VAS    49   7.8    0.7                  7         9         7.0           8.0   8.0
  VAS_1st month   49   2.6    0.6                  1         4         2.0           3.0   3.0
  VAS_3rd month   49   1.2    0.8                  0         3         1.0           1.0   2.0
  VAS_1 year      49   0.7    0.6                  0         3         0.0           1.0   1.0
